• New Lonza Cryopreserved Leukopaks for Immunology & Cell Therapy Research Flexibility

Laboratory Products

New Lonza Cryopreserved Leukopaks for Immunology & Cell Therapy Research Flexibility

Mar 02 2021

Lonza has expanded its renowned human primary cell offerings with the launch of fully customisable, high-quality cryopreserved Leukopaks. The frozen Leukopaks will enable long-distance shipping of leukapheresis products without the concern of reduced cell viability encountered with fresh Leukopaks. Being suitable for long-term storage in research labs, the cryopreserved Leukopaks will also allow immediate access to viable cells for greater convenience and workflow flexibility. The cryopreserved Leukopaks come in a range of sizes, and multiple donor characteristics and testing options are available through a unique costing structure that allows customers to only pay for the customisation that they need.

Andrew Winner, Product Manager at Lonza Bioscience, said: “The short viability window of fresh Leukopaks means researchers are at the mercy of donor and shipping schedules - and any logistical delays can wreak havoc on project costs and the quality of research results. By offering cryopreserved Leukopaks, we are expanding our ability to deliver high-viability cell products internationally, and the rapid availability of stored cryopreserved Leukopaks means our customers are better able to adhere to uncompromising research timelines.”

A Leukopak is an enriched leukapheresis-derived product containing high concentrations of peripheral blood mononuclear cells like T cells, B cells and monocytes. Such cells are a critical raw material in immunotherapy research and for optimising cell therapy process development before progressing to full clinical manufacture. However, fresh Leukopaks can be hard to access and must be used rapidly to avoid cell degradation. International transportation options are thus severely limited, and logistical delays or donor cancellations can have catastrophic impacts on research costs and quality. Cryopreserved Leukopaks allow reliable global shipping while maintaining cell viability and functionality, and the ability to thaw cryopreserved Leukopaks when needed means researchers are better able to plan ahead for more cost-efficient therapy development.

Lonza’s cryopreserved Leukopaks are available in a range of sizes, including packs of 2.5, 5 and 9.5 billion cells, which can be subdivided into separate smaller bags for greater convenience. Specific donor characteristics like age, gender and Human Leukocyte Antigen (HLA) type are also available, with a wide range of recallable donors and several product testing options. Customisation follows a unique, tailored pricing structure, where customers only pay for the customisation they require. Customers will also have access to Lonza’s globally renowned technical support services to facilitate optimised product usage and greater research success.

To find out more about Lonza’s cryopreserved Leukopak offerings, please click here

Digital Edition

Labmate UK & Ireland September 2021

September 2021

In This Edition Articles - The challenges of Biosample access and what needs to change - Innovative UK exports must gather income - not dust Spotlight Life Sciences - How a Pipettin...

View all digital editions


Water Expo Nigeria 2021 - NEW DATES

Sep 21 2021 Lagos, Nigeria

17th Confocal Raman Imaging Symposium

Sep 27 2021 Virtual event

BCEIA 2021

Sep 27 2021 Beijing, China

Photonex & Vacuum Expo

Sep 28 2021 Glasgow, Scotland

Chemspec Digital 2021

Sep 29 2021 Online event

View all events